BACKGROUND: Antihormonal and cytotoxic therapy options are available for the therapy of metastasized prostate cancer (mPC). Because no comparative studies are available, especially for castration-resistant prostate cancer (mCRCP), it remains unclear which patients will profit best from which therapy. OBJECTIVES: Previous data on the sequence of the various therapy options show that correct selection of the first line therapy for mCRPC can have an influence on the prognosis of the patient. In this position paper the various therapy options are critically illustrated and the clinical and pathohistological criteria for selection of the first line therapy of mCRPC are discussed. RESULTS: Molecular markers are an important aid for future patient selection and individualized therapy for optimal use of the available forms of therapy.
BACKGROUND: Antihormonal and cytotoxic therapy options are available for the therapy of metastasized prostate cancer (mPC). Because no comparative studies are available, especially for castration-resistant prostate cancer (mCRCP), it remains unclear which patients will profit best from which therapy. OBJECTIVES: Previous data on the sequence of the various therapy options show that correct selection of the first line therapy for mCRPC can have an influence on the prognosis of the patient. In this position paper the various therapy options are critically illustrated and the clinical and pathohistological criteria for selection of the first line therapy of mCRPC are discussed. RESULTS: Molecular markers are an important aid for future patient selection and individualized therapy for optimal use of the available forms of therapy.
Authors: Emmanuel S Antonarakis; Changxue Lu; Hao Wang; Brandon Luber; Mary Nakazawa; Jeffrey C Roeser; Yan Chen; Tabrez A Mohammad; Yidong Chen; Helen L Fedor; Tamara L Lotan; Qizhi Zheng; Angelo M De Marzo; John T Isaacs; William B Isaacs; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo Journal: N Engl J Med Date: 2014-09-03 Impact factor: 91.245
Authors: Karim Fizazi; Howard I Scher; Arturo Molina; Christopher J Logothetis; Kim N Chi; Robert J Jones; John N Staffurth; Scott North; Nicholas J Vogelzang; Fred Saad; Paul Mainwaring; Stephen Harland; Oscar B Goodman; Cora N Sternberg; Jin Hui Li; Thian Kheoh; Christopher M Haqq; Johann S de Bono Journal: Lancet Oncol Date: 2012-09-18 Impact factor: 41.316
Authors: Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono Journal: N Engl J Med Date: 2012-08-15 Impact factor: 91.245
Authors: Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor Journal: Lancet Date: 2010-10-02 Impact factor: 79.321
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Arun A Azad; Raya Leibowitz-Amit; Bernhard J Eigl; Renee Lester; J Connor Wells; R Nevin Murray; Christian Kollmannsberger; Daniel Y C Heng; Anthony M Joshua; Kim N Chi Journal: Prostate Date: 2014-08-29 Impact factor: 4.104
Authors: Michael T Schweizer; Xian C Zhou; Hao Wang; Sunakshi Bassi; Michael A Carducci; Mario A Eisenberger; Emmanuel S Antonarakis Journal: Eur Urol Date: 2014-01-24 Impact factor: 20.096
Authors: Gwenaelle Gravis; Karim Fizazi; Florence Joly; Stéphane Oudard; Franck Priou; Benjamin Esterni; Igor Latorzeff; Remy Delva; Ivan Krakowski; Brigitte Laguerre; Fréderic Rolland; Christine Théodore; Gael Deplanque; Jean Marc Ferrero; Damien Pouessel; Loïc Mourey; Philippe Beuzeboc; Sylvie Zanetta; Muriel Habibian; Jean François Berdah; Jerome Dauba; Marjorie Baciuchka; Christian Platini; Claude Linassier; Jean Luc Labourey; Jean Pascal Machiels; Claude El Kouri; Alain Ravaud; Etienne Suc; Jean Christophe Eymard; Ali Hasbini; Guilhem Bousquet; Michel Soulie Journal: Lancet Oncol Date: 2013-01-08 Impact factor: 41.316
Authors: Dominik R Berthold; Gregory R Pond; Freidele Soban; Ronald de Wit; Mario Eisenberger; Ian F Tannock Journal: J Clin Oncol Date: 2008-01-10 Impact factor: 44.544
Authors: C-H Ohlmann; P J Goebell; M-O Grimm; J Klier; F König; S Machtens; M Schostak; A-J Schrader; P Albers Journal: Urologe A Date: 2017-12 Impact factor: 0.639